Reaction
Occupational Exposure To Product reporting signals
As of the last recalculation, Occupational Exposure To Product appears in 6,382 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is PEGFILGRASTIM (PRR 59.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pegfilgrastim | 1,412 | 59.6 | 60.5 |
| Erenumab-Aooe | 713 | 47.4 | 48.0 |
| Evolocumab | 956 | 22.4 | 22.6 |
| Blinatumomab | 65 | 20.5 | 20.6 |
| Cabotegravir | 38 | 15.4 | 15.5 |
| Leuprolide Acetate | 333 | 14.7 | 14.8 |
| Denosumab | 553 | 9.7 | 9.7 |
| Sevoflurane | 24 | 9.4 | 9.5 |
| Romosozumab-Aqqg | 38 | 9.2 | 9.2 |
| Romiplostim | 32 | 7.0 | 7.0 |
| Captopril | 17 | 5.8 | 5.8 |
| Carfilzomib | 48 | 5.6 | 5.6 |
| Enoxaparin Sodium | 63 | 3.6 | 3.6 |
| Piperacillin And Tazobactam | 11 | 2.8 | 2.8 |
| Piperacillin Sodium And Tazobactam Sodium | 16 | 2.7 | 2.7 |
| Darbepoetin Alfa | 43 | 2.6 | 2.6 |
| Panitumumab | 12 | 2.5 | 2.5 |
| Zonisamide | 10 | 2.2 | 2.2 |
| Onabotulinumtoxina | 50 | 2.1 | 2.1 |
| Iohexol | 5 | 2.0 | 2.0 |
| Ranibizumab | 15 | 1.8 | 1.8 |
| Faricimab | 4 | 1.6 | 1.6 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 5 | 1.5 | 1.5 |
| Etonogestrel | 21 | 1.4 | 1.4 |
| Rocuronium Bromide | 5 | 1.4 | 1.4 |
| Patiromer | 5 | 1.2 | 1.2 |
| Etanercept | 208 | 1.1 | 1.1 |
| Naltrexone | 10 | 1.1 | 1.1 |
| Medroxyprogesterone Acetate | 14 | 0.9 | 0.9 |